Cargando…
MM-239: A Tertiary Center Experience of Multiple Myeloma Patients with COVID-19: Lessons Learned and the Path Forward
CONTEXT: The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has resulted in over 100,000 deaths in the United States. Our institution has treated over 2,000 COVID-19 patients during the pandemic in New York City. OBJECTIVE: We explored the population of myeloma patients who developed COVID-19 to...
Autores principales: | Wang, Bo, Oekelen, Oliver Van, Mouhieddine, Tarek, Jagannath, Sundar, Parekh, Samir, Madduri, Deepu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834803/ http://dx.doi.org/10.1016/S2152-2650(20)30948-4 |
Ejemplares similares
-
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward
por: Wang, Bo, et al.
Publicado: (2020) -
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward
por: Wang, Bo, et al.
Publicado: (2020) -
NP-114: Lesson Learned: Management of patients with Multiple Myeloma (MM) and their response to two doses of COVID-19 RNA vaccine
por: Verina, Daniel, et al.
Publicado: (2021) -
MM-250: Impact of Prolonged Dose Delays on Response with Belantamab Mafodotin (Belamaf; GSK2857916) Treatment in the DREAMM-2 Study: 13-Month Follow-Up
por: Cohen, Adam D, et al.
Publicado: (2020) -
Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma
por: Sanchez, Larysa, et al.
Publicado: (2021)